Does the FDG Uptake of Primary Non-Small Cell Lung Cancer Predict Prognosis?. A Work in Progress

Yoshifumi Sugawara; Leslie E. Quint; Mark D. Iannettoni; Mark B. Orringer; Joseph E. Russo; Betty E. Recker; Patricia A. Saran; Richard L. Wahl

doi:10.1016/s1095-0397(99)00012-6

Does the FDG Uptake of Primary Non-Small Cell Lung Cancer Predict Prognosis?. A Work in Progress

Clin Positron Imaging. 1999 Mar;2(2):111-118. doi: 10.1016/s1095-0397(99)00012-6.

Authors

Yoshifumi Sugawara¹, Leslie E. Quint, Mark D. Iannettoni, Mark B. Orringer, Joseph E. Russo, Betty E. Recker, Patricia A. Saran, Richard L. Wahl

Affiliation

¹ Division of Nuclear Medicine, Department of Internal Medicine, Ann Arbor, MI, USA

PMID: 14516548
DOI: 10.1016/s1095-0397(99)00012-6

Abstract

OBJECTIVE: To determine if the intensity of fluorine-18-fluorodeoxyglucose (FDG) uptake in primary non-small cell lung cancer (NSCLC) could independently predict patient prognosis.METHODS: Thirty-eight patients with untreated NSCLC were studied with FDG-PET. Primary tumor FDG uptake was calculated by the standardized uptake value based on lean body mass (SUV-lean). Cumulative survival rate and the SUV-lean were compared.RESULTS: There were no significant differences between the tumor stages and the SUV-lean. Although the survival rates significantly decreased as the stage progressed (p =.0049), there was no significant difference in the survival rate between the group with lower primary tumor FDG uptake (SUV-lean </= 8.72) and the group with higher tumor FDG uptake (SUV-lean > 8.72) (p =.2256). However, in the subset of patients without metastasis, survival tended to be longer with a lower tumor SUV-lean.CONCLUSION: In this population of patients with NSCLC, the tumor FDG uptake does not independently predict the prognosis.